Product Information
ACITRETIN 25 MG CAPSULE is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $3.5423 per EA under NDC 00378702393. Its NADAC has been published 543 times since May 11, 2016.
FDA first approved this application on Sep 10, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the acitretin market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
25 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378702393
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACITRETINApproval Type
Generic (ANDA)
FDA Application
ANDA202148FDA Approved
9/10/2015
TE Code
AB
On Market Since
3/10/2016
Pharmacological Classes
Price Statistics
The NADAC for ACITRETIN 25 MG CAPSULE has been published 543 times since May 11, 2016, and over the history we have for it it has declined 84.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.5423 per EA |
|---|---|
| All-time high | $22.4276 (May 11, 2016) |
| All-time low | $3.4171 (Apr 22, 2026) |
| 52-week high | $3.8188 |
| 52-week low | $3.4171 |
| Median price | $9.6485 |
| Average price | $9.9587 |
| Largest weekly change | +62.9% (Oct 18, 2023) |
| Weeks tracked | 543 |
| Tracking since | May 11, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the acitretin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
acitretin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Retinoid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ACITRETIN 25 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ACITRETIN 25 MG CAPSULE, manufactured by Mylan Pharmaceuticals Inc., is $3.5423 per EA (NDC 00378702393), effective Sep 30, 2026.
How has the price of ACITRETIN 25 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for ACITRETIN 25 MG CAPSULE has declined 84.2%. It has been tracked across 543 weekly CMS publications since May 11, 2016.
What are the highest and lowest recorded NADAC prices for ACITRETIN 25 MG CAPSULE?
Since May 11, 2016, the NADAC for ACITRETIN 25 MG CAPSULE has ranged from a low of $3.4171 (Apr 22, 2026) to a high of $22.4276 (May 11, 2016), with a median of $9.6485 per EA.
Are there cheaper alternatives to ACITRETIN 25 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of ACITRETIN 25 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ACITRETIN 25 MG CAPSULE?
ACITRETIN 25 MG CAPSULE (NDC 00378702393) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.